IBI311
IBI311 is a monoclonal antibody that targets IGF-1R and is being developed for thyroid eye disease. It is in a Phase III clinical trial as of 2023.[1][2][3]
References[edit]
- ^ "Innovent doses first patient in Phase III study of IBI311 for TED". Clinical Trials Arena. 8 May 2023. Retrieved 4 November 2023.
- ^ "IGF Market And Pipeline Insights 2023". www.precisionbusinessinsights.com. Retrieved 4 November 2023.
- ^ Li, Chen; Hao, Jun; Wang, Chuangshi; Yang, Jie; Zheng, Yitian; Zhang, Kuo; Hui, Wen; Meng, Xiangbin; Gao, Jun; Li, Wei; Tang, Yi-Da (3 August 2023). "Changes in Drug Clinical Trials of Thyroid Diseases in China, 2009–2022". Drug Design, Development and Therapy. 17: 2315–2324. doi:10.2147/DDDT.S409617. ISSN 1177-8881. PMC 10407876. PMID 37559911.